Biogen Inc (BIIB)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+51% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is product/regulatory, driven by the Japanese approval of the subcutaneous LEQEMBI formulation, with analyst upgrades as a secondary support. Continuation over the next few weeks looks moderately plausible but uncertain, since single-region label expansions often produce a fading move unless followed by broader approvals or commercial traction. Informational only — not financial advice.
- How AbbVie's Neuroscience Portfolio Has Transformed Over the YearsYahoo · 2026-09-16
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s DiseaseYahoo · 2026-09-16
- Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?Yahoo · 2026-09-15
- Hummingbird Bioscience Appoints Dr. James Garner as PresidentYahoo · 2026-09-15
- Biogen Eyes Wave of Phase III Readouts as It Expands Beyond NeuroscienceYahoo · 2026-09-15
Any AI summary is an interpretation of public news, not advice or a price target.